Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Validation of repurposed drugs with antagonist transcriptomic signatures in severe influenza A
2016-004222-42Phase 2Terminated
- Sponsor
- CHU de Lille
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of etilefrine, diltiazem and oseltamivir in Influenza A infection, sponsored by CHU de Lille. Primary endpoint: Virologic response at end of treatment. Started Sep 2017; status: terminated.
02
Drugs
etilefrinediltiazemoseltamivir
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on 2016-004222-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004222-42.